Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation

The programmed death-1 (PD-1) pathway serves as a checkpoint to limit T-cell mediated immune responses. Blocking the PD-1 receptor on T cells with monoclonal anti­bodies results in T-cell activation and proliferation and can induce a potent immuno­therapeutic antitumour effect.